This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Dermatology
  • /
  • Apremilast, an oral phosphodiesterase 4 inhibitor,...

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).

Read time: 1 mins
Published:1st Jan 2016
Author: <p>Rich P,&nbsp;Gooderham M,&nbsp;Bachelez H,&nbsp;Goncalves J,&nbsp;Day RM,&nbsp;Chen R,&nbsp;Crowley J.</p>
Availability: Free full text
Ref.:J Am Acad Dermatol. 2016;74(1):134-42.
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest